In a significant stride towards facilitating safer and more effective drug development, Creative Bioarray is pleased to announce the launch of its flagship hERG safety assay service.

SHIRLEY, NY, January 31, 2026 /24-7PressRelease/ -- Creative Bioarray, a leading provider of high-quality products and services, aims to accelerate research in the biotechnology and drug development fields. In a significant stride towards facilitating safer and more effective drug development, Creative Bioarray is pleased to announce the launch of its flagship hERG safety assay service. As is well known, the safety of new therapies is of paramount importance. Creative Bioarray utilizes advanced assay methods to assess the potential cardiotoxicity of drug candidates to advance the pharmaceutical industry.

Based on the crucial role of hERG channels in cardiac action potentials and rhythms, blockage of these potassium channels can lead to life-threatening cardiac side effects. Drug safety is a critical aspect of pharmaceutical research, and Creative Bioarray has developed a cutting-edge detection method to help researchers identify and mitigate the cardiotoxic risks of compounds early in drug development.

Creative Bioarray's hERG safety assay optimizes traditional screening methods, integrating modern technologies and processes to ultimately deliver high-throughput, reliable results. Furthermore, Creative Bioarray provides clients with detailed data interpretations to help scientists optimize lead compounds while reducing the risk of late-stage drug development failure due to cardiotoxicity.

"Our hERG safety testing service provides a vital tool for pharmaceutical companies and researchers looking to streamline their drug development process," said Hannah Cole, a spokesperson for Creative Bioarray. "Our advanced testing methods provide the critical information needed to make informed decisions and ensure the safety of new therapies. Furthermore, we offer solutions tailored to the specific needs of our clients."

Creative Bioarray's hERG safety assay can be integrated into the early stages of drug development, improving project efficiency and helping to bring safe drugs to market faster. This safety assay is designed to benefit a wide range of stakeholders in the pharmaceutical industry, including biotechnology companies, contract research organizations (CROs), and academic institutions.

Creative Bioarray has cultivated a team of experienced experts with extensive expertise in pharmacology, electrophysiology, and drug safety assessment. This expertise provides clients with not only highly accurate assays but also comprehensive analysis and guidance throughout the research process. In addition to hERG safety testing, Creative Bioarray offers a range of other bioassays, customized services, and products to meet the specific needs of modern research environments.

About Creative Bioarray

Creative Bioarray is a leading provider of bioanalytical services, committed to offering high-quality products and services to clients in the pharmaceutical and biotechnology industries, and capable of delivering tailored, high-quality solutions. Currently, Creative Bioarray is dedicated to supporting advancements in global scientific research, driven by a strong commitment to innovation and customer satisfaction.

Read the full story here: https://www.24-7pressrelease.com/press-release/531317/creative-bioarray-launches-comprehensive-herg-safety-assay-service-to-enhance-drug-development

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire